Helix BioPharma Corp. Announces Appointment of New

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Helix BioPharma Corp. Announces Appointment of New Directors to the Board of Directors

AURORA, ON--(Marketwired - Jan 29, 2016) - Helix BioPharma Corp. ( TSX : HBP ) ( FRANKFURT : HBP ), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, has today announced the appointment of Mr. Albert Beraldo and Mr. George J. Anders to the board of directors. The appointments are effective as of January 28, 2016. At the same time, Mr. Gary Littlejohn and Mr. Yvon Bastien submitted their resignations to the board of directors for its consideration.

Mr. Albert Beraldo is the former founder/ President and CEO of Alveda Pharmaceuticals Inc., a privately owned Canadian company that is a leading supplier of pharmaceuticals to the Canadian health care market. IGI Laboratories, Inc., a New Jersey-based specialty generic pharmaceutical company, announced in October 2015 it has entered into an agreement to acquire the assets of Alveda Pharmaceuticals, Inc. The transaction was closed on November 13, 2015.

Mr. Beraldo formerly served as the President and CEO of Bioniche Pharma Group Limited until 2006. He also previously served as a Director of Bioniche Life Sciences Inc. from 1984 to 2005. Mr. Beraldo holds a Bachelor of Commerce degree from the University of Windsor and has a Chartered Accountant designation from the Canadian Institute of Chartered Accountants. Mr. Beraldo worked in public accounting with Ernst and Whinney until he joined Vetrepharm Canada Inc. as a Financial Controller in 1983.

Mr. George Anders is the President of Anders Consulting. Between 1975 and 2012 he was employed by Ontario Hydro and its successor companies in Toronto, Canada. He was a Principal Engineer/Scientist in the Electrical Systems Technologies Department of Kinectrics Inc. for many years. Dr. Anders is a Professor at the Faculty of Electrical and Electronic Engineering of the Technical University of Lodz in Poland and an Adjunct Professor in the Department of Electrical and Computer Engineering at the University of Toronto. Dr. Anders is a registered Professional Engineer in the Province of Ontario and a Fellow of IEEE. He is also a Project Management Professional registered with the Project Management Institute.

Commenting on the appointment, the Chairman of the Board, Dr. Sven Rohmann said, " Mr. Beraldo and Prof. Anders perfectly complement the board skills, fostering strategic planning and adding decades of experience in varying leadership roles within the industry, including deal-making, M&A transactions and serving the financial markets ."

Dr. Zbigniew Markowski, the CEO, said, " I feel that we now have the excellence on board necessary to achieve the milestones according to our strategy and to start the growth of the Company. I warmheartedly welcome Mr. Beraldo and Prof. Anders. "

At the same time, the Board of Directors accepted both Mr. Gary Littlejohn's and Mr. Yvon Bastien's resignations.

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About L-DOS47 clinical development

L-DOS47 is currently being clinically evaluated in two clinical studies, in the United States and Poland and, as a treatment for certain patients with non-small cell lung cancer ("NSCLC").

LDOS001 is a Phase I, open-label, dose escalation study being conducted in the United States at three centers: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination.

LDOS002 is an open-label Phase I/II clinical study being conducted in Poland to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. Patients are being enrolled in the fifteenth dosing cohort at a dose of 10.19 micrograms of L-DOS47 per kilogram of patient body weight.

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking information") within the meaning of applicable Canadian securities laws. Forward-looking information means disclosure regarding possible events, conditions or other matters that is based on assumptions about future economic conditions and courses of action and includes statements regarding plans, goals, objectives, intentions and expectations with respect to Helix's future business, operations, research and development, including Helix's activities relating to L-DOS47 and other information in future periods. Forward-looking information includes, without limitation, statements relating to the patients participating in the LDOS001 and LDOS002 clinical studies and the potential of LDOS001 to provide information on the use of L-DOS47 as a potential first-line therapy in combination with the standard of care in NSCLC, and other statements which may be identified by words including, without limitation, "continue", "expect", "intend" and other similar expressions, which are intended to provide information about management's current plans and expectations regarding the conduct of the clinical studies of L-DOS47 and the other operations of Helix.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully, including that patient recruitment for the Polish Phase I/II clinical trial for L-DOS47 does not continue as scheduled or at all, and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Report, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Investor Relations: Helix BioPharma Corp. 3-305 Industrial Parkway South Aurora, Ontario, L4G 6X7 Tel: 905 841-2300 Email: ir@helixbiopharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 0

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 51

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 416

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 40

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 51

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 372

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 0

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 25

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 5

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 27

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading

Top 5 Most Recently Viewed Articles

Labcon and Polycarbin Forge Sustainable Partnership for Labs

Updated Category News Views 93

Labcon Teams Up with Polycarbin for Sustainable Solutions Labcon North America, known for its commitment to Earth Friendly® laboratory disposables, is partnering with Polycarbin, a leader in sustainable laboratory solutions. This strategic alliance aims to promote a circular economy within the life sciences and pharmaceutical industries. Joining Forces for Circular...

Continue Reading
Toobit Innovates with New Card Payment for Cryptocurrency Purchases

Updated Category News Views 141

Toobit Introduces Hassle-free Cryptocurrency Purchases Toobit, a leading name in the cryptocurrency market, is breaking new ground by launching a feature that allows users to buy digital currencies using credit and debit cards. This innovative approach is set to simplify the purchasing process, enabling customers to engage in the world of cryptocurrencies with ease and...

Continue Reading
Exploring the UAE's Growing $40.8 Billion Wellness Landscape

Updated Category News Views 222

The UAE's Flourishing Wellness Economy In collaboration with key stakeholders, recent findings indicate that the wellness economy in the UAE has experienced impressive growth of 14.3% from 2019 to 2024. This demonstrates its status as the fastest-growing wellness market in the region. Valuation of the Wellness Sector The value of the wellness industry in the UAE has...

Continue Reading
Waylens Partners with Greater Than for Enhanced Fleet Safety

Updated Category News Views 165

Waylens and Greater Than Join Forces for Fleet Safety In an exciting development for the fleet management industry, Waylens, recognized for its cutting-edge AI video telematics technology, is partnering with Greater Than, a leading provider of risk intelligence focused on road safety and climate impacts. This collaboration aims to enhance fleet safety by integrating video...

Continue Reading
Heavy Options Trading Indicates Optimism for NuScale Power

Updated Category News Views 185

NuScale Power Sees Significant Options Activity Investors are increasingly showing a positive outlook towards NuScale Power (NYSE: SMR), an engagement worth noting in the market landscape. Recent tracking of public options records has revealed notable movements among deep-pocketed investors today. Understanding the Options Landscape Today, the options scanner brought to...

Continue Reading